



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/816,546	03/26/2001	Deborah J. Good	P 0279282	9489

909 7590 11/21/2002
PILLSBURY WINTHROP, LLP
P.O. BOX 10500
MCLEAN, VA 22102

EXAMINER

CHEN, SHIN LIN

ART UNIT PAPER NUMBER

1632

DATE MAILED: 11/21/2002

12

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/816,546

Applicant(s)

Good et al.

Examiner

Shin-Lin Chen

Art Unit

1632



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Oct 28, 2002
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-49 is/are pending in the application.
- 4a) Of the above, claim(s) 10-21 and 31-49 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9 and 22-30 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on Nov 20, 2001 is/are a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 6) ☐ Other:

Art Unit: 1633

DETAILED ACTION

1. Applicant's election without traverse of group I, claims 1-9 and 22-30, in Paper No. 11 is acknowledged.

2. Claims 10-21 and 31-49 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in Paper No. 11.

Claims 1-49 are pending and claims 1-9 and 22-30 are under consideration.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claim 4 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The phrase "PGK promoter" in claim 4 is vague and renders the claim indefinite. It is unclear what PGK stands for and it is unclear as to the metes and bounds of what would be considered "PGK promoter". The specification fails to define the term "PGK".

5. Claim 1 recites the limitation "said bovine" in line 4. There is insufficient antecedent basis for this limitation in the claim. Claims 2-9 and 22-27 depend on claim 1 but fail to clarify the indefiniteness.

Art Unit: 1633

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1-9 and 22-30 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making a transgenic ungulate bearing a homozygous deletion of prion gene by transfecting bovine embryonic fibroblast (BEF) cells with targeting vector and nuclear transfer technique, does not reasonably provide enablement for using said transgenic ungulate, making and using any transgenic ungulate comprising any targeted gene deletion having a particular phenotype, and using transgenic ungulate bearing a heterologous deletion of the prion gene, wherein said transgenic ungulate is less susceptible to prion-related disease. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Claims 1-9 and 22-27 are directed to a transgenic ungulate having a homozygous deletion or disruption of the prion gene via homologous recombination of heterologous DNA, such as neo marker gene, into the prion gene locus that renders the transgenic ungulate unsusceptible to prion-related diseases, the cloned transgenic ungulate, and the line of transgenic ungulate.

Claims 8, 9 and 23-25 specify the transgenic ungulate bears a heterologous gene extraneous to the prion gene locus and said heterologous gene is under the control of mammary-specific

Art Unit: 1633

promoter for production of a protein in the milk of said transgenic ungulate. Claims 28 and 29 are directed to a transgenic ungulate or bovine comprising a targeted gene deletion. Claim 30 is directed to a transgenic ungulate bearing a heterozygous deletion of the prion gene and said ungulate is less susceptible to prion-related diseases.

The specification discloses isolation of bovine prp gene and optimization of G418 drug selection of BEF cells transfected with pPNT vector. The specification teaches protocols for transfecting BEF cells with prp targeting vector and making of transgenic ungulate via nuclear transfer.

The claims encompass using any transgenic ungulate bearing a homozygous or heterozygous deletion or disruption of prion gene. The specification fails to provide adequate guidance for how to use the claimed transgenic ungulates. The specification indicates that the transgenic ungulates of the present application can be used as the source of cells and tissues for xenotransplantation in treating diseases, such as Parkinson's disease or Huntington disease. However, it was known in the art that immunological rejection is still a hurdle in xenotransplantation. Larsson et al., 2000 (Scandinavian Journal of Immunology, Vol. 52, No. 3, p. 249-256) teaches that pig embryonic neural tissue has been grafted to patients with Parkinson's disease with no clinically proven benefits and immunorejection of neural xenograft by the patients renders the treatments insufficient (e.g. abstract). Although brain is an organ with partial immune privilege, the immune privilege is not absolute and both allografts and xenografts are rejected in the brain. "In discordant xenogeneic species combinations, there are

Art Unit: 1633

incompatibilities in the complement cascade and natural antibodies against the donor are present in the host blood circulation...later appearing cellular mechanisms, important for allograft rejection, are also important for discordant xenograft rejection. A discordant xenogeneic organ is rejected within minutes or hours in a process involving complement and antibodies, termed hyperacute rejection" (e.g. page 252).

Further, Barker et al., 2000 (Cell Transplantation, Vol. 9, No. 2, p. 235-246) teaches that major issues for neural tissue xenografting include issue of safety in terms of the tissue itself, the neurological procedure, and the risks of immunosuppression, issues of survival and function, and the extent to which questions have to be answered in the laboratory before use, and issues relating to the immunosuppression that xenografting will entail (e.g. p. 236, right column). The specification must provide an enabling disclosure for the use of the claimed transgenic ungulates but fails to do so. There is no evidence of record that the transgenic ungulate can be used for xenografting for Parkinson's disease or Huntington's disease or other diseases. Thus, one skilled in the art at the time of the invention would not know how to use the claimed transgenic ungulate.

Claims 28 and 29 encompass any transgenic ungulate or bovine having any targeted gene deletion. Claim 30 encompasses any transgenic ungulate bearing a heterozygous deletion of the prion gene that renders said ungulate less susceptible to prion-related diseases. The specification fails to provide adequate guidance and evidence for the production and use of a transgenic ungulate having **any targeted gene** deletion or **heterozygous deletion** of prion gene other than

Art Unit: 1633

homozygous deletion of prion gene. The specification also fails to provide adequate guidance and evidence that a transgenic ungulate having heterozygous deletion of prion gene would render said ungulate less susceptible and to what extent of less susceptible to prion-related diseases.

The state of the art in the fields of transgenic animal at the time of the invention was unpredictable, the transgene expression and resulting phenotype of such expression is not always accurately predictable. Kappel et al., 1992 (*Current Opinion in Biotechnology*, Vol. 3, p. 548-553) reports that the individual gene of interest, promoter, enhancer, coding or non-coding sequences present in the transgene construct, the site of integration, etc., are the important factors that governs the expression of a transgene (e.g. p. 549)). Similarly, it was unpredictable for generating transgenic animals harboring any disrupted gene. Wu et al., 1997 (*Methods in Gene Biotechnology*, CRC Press, Boca Raton, p. 339-365) pointed out that the approach of using ES cells carrying a single-copy mutation of a specific gene to generate knockout transgenic animal is time-consuming and costly to obtain homozygous or double-knockout mice, and another major concern is the potentially lethal effect of the targeted gene. In some cases, gene knockout results in early death of embryos and young animals, or morphologically and functionally abnormal offsprings such as blind and/or handicapped animals.

Further, Sigmund, June 2000 (*Arterioscler. Thromb. Vasc. Biol.*, p. 1425-1429), reports that variation in the genetic background contributes to unpredictable resulting phenotypes of transgenic or gene-targeted animals. "Animals containing the same exact genetic manipulation exhibit profoundly different phenotypes when present on diverse genetic backgrounds,

Art Unit: 1633

demonstrating that genes unrelated, per se, to the ones being targeted can play a significant role in the observed phenotype” (abstract). Sigmund further states that “many of the phenotypes examined in transgenic and knockout models are influenced by the genetic background in which they are studies...Although all mouse strains contain the same collection of genes, it is allelic variation...and the interaction between allelic variants that influence a particular phenotype. These “epigenetic” effects can dramatically alter the observed phenotype and therefore can influence or alter the conclusions drawn from experiments” (e.g. introduction). Therefore, the resulting phenotypes of the claimed transgenic ungulates having any targeted gene deletion other than transgenic ungulates having homozygous deletion of prion gene would be unpredictable at the time of the invention. Thus, one skilled in the art at the time of the invention would not know how to use the claimed transgenic ungulates.

For the reasons discussed above, it would have required undue experimentation for one skilled in the art at the time of the invention to practice over the full scope of the invention claimed. This is particularly true given the nature of the invention, the state of the prior art, the breadth of the claims, the amount of experimentation necessary, the absence of working examples and scarcity of guidance in the specification, and the unpredictable nature of the art.

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1633

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 1-3, 5-9 and 22-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Weissmann et al., 1997 (Us Patent No. 5,698,763) in view of Wu et al., 1997 (Methods in Gene Biotechnology, CRC Press, Boca Raton, p. 339-365) and Shani et al., 1992 (Transgenic Research, Vol. 1, No. 5, p. 195-208).

Claims 1-3, 5-9 and 22-27 are directed to a transgenic ungulate having a homozygous deletion or disruption of the prion gene via homologous recombination of heterologous DNA, such as neo marker gene, into the prion gene locus that renders the transgenic ungulate unsusceptible to prion-related diseases, the cloned transgenic ungulate, and the line of transgenic ungulate. Claims 8, 9 and 23-25 specify the transgenic ungulate bears a heterologous gene extraneous to the prion gene locus and said heterologous gene is under the control of mammary-

Art Unit: 1633

specific promoter for production of a protein in the milk of said transgenic ungulate. Claims 28 and 29 are directed to a transgenic ungulate or bovine comprising a targeted gene deletion.

Weissmann teaches using DNA targeting molecules that specifically disrupt prp genes by homologous recombination in transfected animal cells, culturing the transfected animal cells, and producing transgenic mammals, such as sheep, pigs, and cattle, having deleted prp gene and the transgenic progeny of said mammals. Weissmann also teaches using neomycin or hygromycin selectable marker gene under the control of HSV TK promoter in the DNA targeting vector for selection of the transfected cells (e.g. abstract, column 6). Weissmann produced a transgenic mouse having homozygous deletion of the prp gene and showed its resistance to Scrapie infection (e.g. column 13, 14).

Weissmann does not teach using a heterologous gene, under the control of a mammary-specific promoter, extraneous to the prion gene locus and the production of a recombinant protein in the milk of the transgenic ungulate.

Wu teaches a method of making a transgenic knockout animal by using DNA targeting vector comprising hygromycin (hyg) or neomycin (neo), LaZ and HSV-TK selection marker genes, wherein hyg or neo, and LaZ genes are inserted into target gene locus via homologous recombination, however, the HSV-TK gene is outside the target gene locus (e.g. Figure 17.5-17.7).

Shani teaches generating transgenic mice expressing sheep beta-lactoglobulin (BLG) or human serum albumin (HSA) under the control of the sheep BLG promoter sequence and

Art Unit: 1633

demonstrates that high levels of HSA can be expressed in the milk of transgenic mice (e.g. abstract).

It would have been obvious for one of ordinary skill at the time of the invention to include a heterologous gene as taught by Weissmann, Wu and Shani in the DNA targeting vector as taught by Weissmann and Wu because it was known in the art to express a heterologous gene in a transgenic animal for the production of its gene product and it would be obvious to one of ordinary skill.

One having ordinary skill at the time the invention was made would have been motivated to do so in order to express a recombinant protein in the milk of a transgenic animal by using a mammary-specific promoter, such as beta-BLG promoter, as taught by Shani with reasonable expectation of success.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (703) 305-1678. The examiner can normally be reached on Monday to Friday from 9 am to 5:30 pm.

Art Unit: 1633

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds can be reached on (703) 305-4051. The fax phone number for this group is (703) 308-4242.

Questions of formal matters can be directed to the patent analyst, Patsy Zimmerman, whose telephone number is (703) 305-2758.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Shin-Lin Chen, Ph.D.

A handwritten signature in black ink, appearing to read 'shchen', is located below the typed name 'Shin-Lin Chen, Ph.D.'.